Seroatlas · Human Serome Atlas

TRIT1

tRNA dimethylallyltransferase

Also known as: FLJ20061, IPT, MOD5_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9H3H1
Gene
TRIT1
Ensembl
ENSG00000043514
Chromosome
1
Canonical length
467 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
Subcellular location
Mitochondria

OverviewNCBI Gene

This gene encodes a protein that that is targeted to the mitochondrion and modifies transfer RNAs (tRNAs) by adding a dimethylallyl group onto the adenine at position 37. This modification is important for maintaining the correct reading frame during protein translation. This gene is considered a tumor suppressor and its expression can decrease cell growth. Alternative splicing results in multiple transcripts variants, most of which are likely non-functional. [provided by RefSeq, Aug 2015]

Canonical amino-acid sequenceUniProt

467 residues, UniProt reviewed canonical sequence.

>Q9H3H1|TRIT1
     1  MASVAAARAV PVGSGLRGLQ RTLPLVVILG ATGTGKSTLA LQLGQRLGGE IVSADSMQVY
    61  EGLDIITNKV SAQEQRICRH HMISFVDPLV TNYTVVDFRN RATALIEDIF ARDKIPIVVG
   121  GTNYYIESLL WKVLVNTKPQ EMGTEKVIDR KVELEKEDGL VLHKRLSQVD PEMAAKLHPH
   181  DKRKVARSLQ VFEETGISHS EFLHRQHTEE GGGPLGGPLK FSNPCILWLH ADQAVLDERL
   241  DKRVDDMLAA GLLEELRDFH RRYNQKNVSE NSQDYQHGIF QSIGFKEFHE YLITEGKCTL
   301  ETSNQLLKKG IEALKQVTKR YARKQNRWVK NRFLSRPGPI VPPVYGLEVS DVSKWEESVL
   361  EPALEIVQSF IQGHKPTATP IKMPYNEAEN KRSYHLCDLC DRIIIGDREW AAHIKSKSHL
   421  NQLKKRRRLD SDAVNTIESQ SVSPDHNKEP KEKGSPGQND QELKCSV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TRIT1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.32
Highest tissue expression
20 nTPM

Expression across tissuesHPA

Tissue

  • skin: 20 nTPM
  • pancreas: 19 nTPM
  • prostate: 19 nTPM
  • cerebellum: 17 nTPM
  • esophagus: 17 nTPM
  • pituitary gland: 16 nTPM

Single-cell type

  • sertoli cells: 118 nCPM
  • cardiomyocytes: 105 nCPM
  • respiratory deuterosomal cells: 72 nCPM
  • retinal pigment epithelial cells: 64 nCPM
  • respiratory ciliated cells: 62 nCPM
  • choroid plexus epithelial cells: 61 nCPM

Immune cell

  • myeloid DC: 10 nTPM
  • plasmacytoid DC: 10 nTPM
  • classical monocyte: 5.4 nTPM
  • non-classical monocyte: 5.3 nTPM
  • intermediate monocyte: 3.9 nTPM
  • MAIT T-cell: 3.7 nTPM

Brain region

  • cerebellum: 12 nTPM
  • white matter: 11 nTPM
  • cerebral cortex: 11 nTPM
  • hypothalamus: 10 nTPM
  • basal ganglia: 8.3 nTPM
  • hippocampal formation: 8.3 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TRIT1.

Disease | AllUniProt

Conditions TRIT1 is implicated in, by any mechanism.

  • Combined oxidative phosphorylation deficiency 35 (COXPD35) MIM:617873

Disease | GeneticClinVar

17 pathogenic / likely-pathogenic of 188 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.14
gnomAD pLI
0
gnomAD missense Z
0.78
DepMap mean gene effect
-0.17
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TRIT1 as an antibody target. Whether an autoantibody or antibody against TRIT1 could matter depends on whether native TRIT1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TRIT1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label TRIT1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/TRIT1. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...